| Bioactivity | S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer drug resistance[1]. |
| Target | AKR1C3 |
| Invitro | S07-2001 (50 μM) reduces 27% of MCF-7 cell viability administrated with Doxorubicin[1]. |
| Name | S07-2001 |
| CAS | 1197904-57-6 |
| Formula | C15H17N3O4S |
| Molar Mass | 335.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Siyu He, et al. Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. ACS Med. Chem. Lett. Jun 2022. |
S07-2001
CAS: 1197904-57-6 F: C15H17N3O4S W: 335.38
S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 e
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.